Sciele Pharma, Inc. is a pharmaceutical company specializing in sales, marketing and development of branded prescription products focused on Cardiovascular, Diabetes, Women's Health and Pediatrics. The Company's Cardiovascular and Diabetes products treat patients with high cholesterol, hypertension, high triglycerides, unstable angina and Type 2 diabetes; its Women's Health products are designed to improve the health and well-being of women and mothers and their babies; and its Pediatrics products treat allergies, asthma, coughs and colds, and attention deficit/hyperactivity disorder (ADHD).

Founded in 1992 and headquartered in Atlanta, Georgia, Sciele Pharma employs more than 1,000 people. The Company's success is based on placing the needs of patients first, improving health and quality of life, and implementing its business platform - an Entrepreneurial Spirit, Innovation, Execution Excellence, Simplicity, and Teamwork.

Recent News

Shionogi Completes Acquisition of Sciele

Shionogi and Sciele Announce Completion of Subsequent Offering Period

Shionogi and Sciele Announce Successful Tender Offer and Commencement of Subsequent Offering

Shionogi and Sciele Announce Receipt of United States Antitrust Clearance

Sciele Completes Pivotal Phase III Program for Glycopyrrolate in Pediatric Patients with Chronic, Moderate-to-Severe Drooling

Sciele Pharma and Addrenex Pharmaceuticals Announce Positive Phase III Clinical Results of Clonicel for ADHD